8-K: LIXTE Biotechnology Expands Clinical Trial for Ovarian Cancer Treatment with Northwestern University's Lurie Cancer Center

LIXTE Biotechnology Holdings, Inc. announces the addition of Northwestern University's Lurie Cancer Center as a second site for its clinical trial combining LB-100 with GSK's Dostarlimab to treat ovarian clear cell cancer, with patient recruitment underway and the first patient dosed.

Summary

• LIXTE Biotechnology Holdings, Inc. has added Northwestern University's Lurie Cancer Center as a second clinical trial site.
• The trial is evaluating the combination of LIXTE's LB-100 and GSK's Dostarlimab for treating ovarian clear cell cancer.
• Patient recruitment is underway, and the first patient at Lurie Cancer Center has been dosed.
• The initial clinical trial site is at The University of Texas MD Anderson Cancer Center, initiated in January 2024.
• LB-100 is a first-in-class PP2A inhibitor with the potential to improve outcomes for patients undergoing chemotherapy or immunotherapy.

Sentiment

Score: 7

Explanation: The announcement is positive due to the expansion of the clinical trial and the involvement of a reputable cancer center. However, it is still early in the trial process, and there are inherent risks associated with drug development.

Positives

• The addition of Lurie Cancer Center expands the patient population for the clinical trial.
• The expansion may accelerate the clinical trial process.
• LB-100 has shown to be well-tolerated in cancer patients at doses associated with anti-cancer activity.
• LB-100 has the potential to significantly improve outcomes for patients undergoing various chemotherapies or immunotherapies.

Risks

• The forward-looking statements are subject to known and unknown risks and uncertainties.
• Regulatory policies, available cash resources, research results, competition, and market and general economic factors could cause actual results to differ materially.

Future Outlook

The company is focused on the continuing development of proprietary compounds, the planning, funding, coordination and potential results of clinical trials, the patent and legal costs to protect and maintain the company's intellectual property worldwide, and the company's ability to obtain and maintain compliance with Nasdaq's continued listing requirements.

Management Comments

• Dr. Hinchcliff stated that clinical trials are essential to move the field forward and is pleased to participate in the trial to assess whether adding LIXTE's LB-100 to GSK's Dostarlimab will enhance the effectiveness of immunotherapy.
• Bas van der Baan, LIXTE's CEO, said that the addition of Lurie Cancer Center is a positive step in expanding the patient population and accelerating the clinical trial.

Industry Context

This announcement reflects the ongoing efforts in the pharmaceutical industry to develop new and effective cancer therapies, particularly through the combination of different treatment modalities like targeted therapies and immunotherapies. The collaboration with a renowned cancer center like Lurie Cancer Center highlights the importance of academic-industry partnerships in advancing clinical research.

Comparison to Industry Standards

• GSK's Dostarlimab is an established immunotherapy drug, and combining it with a novel PP2A inhibitor like LB-100 is a strategy to potentially overcome resistance or enhance efficacy, similar to other combination therapies being explored in oncology.
• Many pharmaceutical companies are exploring combination therapies to improve cancer treatment outcomes, such as Merck's Keytruda with various chemotherapy regimens or targeted therapies.
• The involvement of a National Cancer Institute-designated Comprehensive Cancer Center like Lurie Cancer Center adds credibility and expertise to the clinical trial, aligning with industry best practices for clinical research.

Stakeholder Impact

• Positive impact on patients with ovarian clear cell cancer by potentially providing a new treatment option.
• Positive impact on LIXTE Biotechnology shareholders due to the advancement of the company's clinical program.
• Positive impact on the medical community through the generation of clinical data and potential advancements in cancer treatment.

Next Steps

• Continue patient recruitment at both clinical trial sites.
• Assess the effectiveness of the LB-100 and Dostarlimab combination therapy.
• Monitor patient outcomes and safety data.
• Advance the clinical development of LB-100.

Key Dates